Lv1
78 积分 2025-07-18 加入
Bruton tyrosine kinase inhibitors for multiple sclerosis
2个月前
已完结
Initial safety and efficacy results from a first-in-human, phase 1/2 study of SAR445877, an anti-PD-1/IL-15 fusion protein, for patients with advanced solid tumors
4个月前
已关闭
A first-in-class JAK/ROCK inhibitor, rovadicitinib, for glucocorticoid-refractory or -dependent chronic GVHD
4个月前
已完结
Remibrutinib in Chronic Spontaneous Urticaria
5个月前
已完结
Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation
5个月前
已完结
Prognostic risk models for transplant decision-making in myelofibrosis
5个月前
已完结
A first-in-class JAK/ROCK inhibitor, Rovadicitinib in patients with myelofibrosis who were refractory or relapsed or intolerant to Ruxolitinib: A single-arm, multicenter, open-label, phase Ib study
5个月前
已完结
Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial
7个月前
已完结
Teplizumab: First Approval
8个月前
已完结
Teplizumab delays onset of type 1 diabetes mellitus
8个月前
已完结
皖公网安备34019202002308
